• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunoprecise Antibodies Ltd (NQ: IPA )

    0.6250 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 500
    Open 0.6250
    Bid (Size) 0.6250 (5)
    Ask (Size) 0.6500 (50)
    Prev. Close 0.6250
    Today's Range 0.6250 - 0.6250
    52wk Range 0.4950 - 2.600
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire

    Performance

    YTD
    -63.24%
    -63.24%
    1 Month
    -6.65%
    -6.65%
    3 Month
    -37.50%
    -37.50%
    6 Month
    -55.99%
    -55.99%
    1 Year
    -59.42%
    -59.42%

    More News

    Read More
    ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    Earnings Outlook For ImmunoPrecise Antibodies
    Via Benzinga
    IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    EXCLUSIVE: ImmunoPrecise Antibodies' Subsidiary Releases Software With Customizable Interface For AI-Driven Drug Discovery
    Via Benzinga
    IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
    Via ACCESSWIRE
    ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
    Via ACCESSWIRE
    InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications
    Via Benzinga
    IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024
    Via InvestorPlace
    IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
    From ImmunoPrecise Antibodies Ltd.
    Via Business Wire
    Earnings Scheduled For March 14, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.